Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

• Status: Recruiting
• Trial end date: 2024-06-24
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Royal Perth Hospital
• Collaborator: The University of Western Australia
• Treatments: Amlodipine; Moxonidine

Criteria

Inclusion Criteria:

• Age: 25 -65 years

• (Body Mass Index) BMI≥30kg/m2

• Currently weight stable (+/- 3% in previous 6-12 months and not on any specific exercise or dietary program)

• Elevated clinic systolic (Blood Pressure) BP ≥135 or diastolic BP ≥85mmHg,

• on ACE inhibitor for at least 6 weeks prior to baseline assessment

Exclusion Criteria:

• Grade 2-3 hypertension (systolic office BP >160, diastolic office BP >100 mmHg)

• Secondary causes of hypertension

• CKD (Chronic kidney disease) stage 4-5 {(estimated glomerular filtration) eGFR<30ml/min}

• Heart failure NYHA (New York Heart Association) class II-IV

• Recent CV (cardiovascular) event (acute myocardial infarction, acute coronary syndrome, stroke or transient ischaemic attack within the previous six months) unstable psychiatric condition

• medication such as corticosteroids, several antidepressants and antipsychotics

• Female participants of childbearing potential must have a negative pregnancy test prior to treatment